The Effect of Aspirin on Pulmonary Fibrotic Lesions and Oxidative Stress Induced by Bleomycin in Pulmonary Tissue of Rat

Document Type : Original Article (s)

Authors

1 Student of Pharmacy, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Pharmacology and Toxicology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

4 Assistant Professor, Department of Pathology, School of Veterinary Medicine, Razi University, Kermanshah, Iran

Abstract

Background: Idiopathic pulmonary fibrosis is a chronic and inflammatory disease of lung which lead to formation of collagen in its tissue. Due to the inflammatory nature of fibrosis, this study aimed to evaluate the effectiveness of different doses of aspirin on bleomycin-induced pulmonary fibrosis.Methods: The current study were done on male adult Wistar rats whom were randomly divided into groups with 6 animals in each. Sham group, control group, bleomycin groups which respectively received 15 units/kg bleomycin intraperitoneally (IP) or 5 units/kg bleomycin by intratracheal instillation, and aspirin groups which respectively received 50, 100, or 150 mg/kg aspirin by gavage concomitant with the intraperitoneal bleomycin. The treatment of animals lasted 28 days; and then the lung tissue was removed for histological examination and measurement of hydroxyproline and malondialdehyde levels.Findings: The same as intratracheal instillation of bleomycin, its intraperitoneal injection caused a significant increase in hydroxyproline and malondialdehyde levels in rat lung tissue (P < 0.001). Administration of aspirin for 28 consecutive days significantly reduced the levels of hydroxyproline and malondialdehyde in bleomycin-induced pulmonary fibrotic rats (P < 0.001). In addition, it caused a significant improvement in histological factors indicating inflammation and fibrosis. There was no significant difference in fibrotic and inflammatory indexes between the studied doses of aspirin.Conclusion: Intraperitoneal injection of bleomycin caused pulmonary fibrosis in rat’s pulmonary tissue the same as when bleomycin instilled intratracheally. Aspirin remarkably improved bleomycin-induced pulmonary fibrosis and oxidative stress. There was no difference in the effectiveness of the studied doses of aspirin. The exact involving mechanisms of aspirin and its effect in other doses need to be more investigated.

Keywords

References

  1. Kim HJ, Perlman D, Tomic R. Natural history of idiopathic pulmonary fibrosis. Respir Med 2015; 109(6): 661-70.
  2. Daba MH, El-Tahir KE, Al-Arifi MN, Gubara OA. Drug-induced pulmonary fibrosis. Saudi Med J 2004; 25(6): 700-6.
  3. Mouratis MA, Aidinis V. Modeling pulmonary fibrosis with bleomycin. Curr Opin Pulm Med 2011; 17(5): 355-61.
  4. Pleasants R, Tighe RM. Management of Idiopathic Pulmonary Fibrosis. Ann Pharmacother 2019; 53(12): 1238-48.
  5. Covvey JR, Mancl EE. Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis. Ann Pharmacother 2014; 48(12): 1611-9.
  6. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012; 380(9842): 680-8.
  7. Pihlaja R, Haaparanta-Solin M, Rinne JO. The Anti-Inflammatory Effects of Lipoxygenase and Cyclo-Oxygenase Inhibitors in Inflammation-Induced Human Fetal Glia Cells and the Abeta Degradation Capacity of Human Fetal Astrocytes in an Ex vivo Assay. Front Neurosci 2017; 11: 299.
  8. Zhang CY, Duan JX, Yang HH, Sun CC, Zhong WJ, Tao JH, et al. COX-2/sEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence. FEBS J 2020; 287(8): 1666-80.
  9. Arafa HM, Abdel-Wahab MH, El-Shafeey MF, Badary OA, Hamada FM. Anti-fibrotic effect of meloxicam in a murine lung fibrosis model. Eur J Pharmacol 2007; 564(1-3): 181-9.
  10. Rosa AC, Pini A, Lucarini L, Lanzi C, Veglia E, Thurmond RL, et al. Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment. J Pharmacol Exp Ther 2014; 351(2): 308-16.
  11. Chandler DB, Young K. The effect of diclofenac acid (Voltaren) on bleomycin-induced pulmonary fibrosis in hamsters. Prostaglandins Leukot Essent Fatty Acids 1989; 38(1): 9-14.
  12. Mall G, Zimmermann P, Siemens I, Burkhardt A, Otto HF. Prevention of bleomycin-induced fibrosing alveolitis with indomethacin: stereological studies on rat lungs. Virchows Arch A Pathol Anat Histopathol 1991; 419(4): 339-47.
  13. Desborough MJR, Keeling DM. The aspirin story - from willow to wonder drug. Br J Haematol 2017; 177(5): 674-83.
  14. Della L, V, Cecchettini A, Del RS, Morales MA. Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions. Pharmacol Res 2015; 97: 122-30.
  15. Klopfleisch R. Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology--a systematic review. BMC Vet Res 2013; 9: 123.
  16. Hubner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 2008; 44(4): 507.
  17. Ren Y, Zhao J, Shi Y, Chen C, Chen X, Lv C. Simple determination of L-hydroxyproline in idiopathic pulmonary fibrosis lung tissues of rats using non-extractive high-performance liquid chromatography coupled with fluorescence detection after pre-column derivatization with novel synthetic 9-acetylimidazol-carbazole. J Pharm Biomed Anal 2017; 142: 1-6.
  18. Roshan Zamir T, Alavi SA, Ghassami F, Mirkheshti N, Ansari L. The therapeutic effect of colchicine on delayed pulmonary injury of sulfur mustard in animal model. J Isfahan Med Sch 2011; 28(122): 1765-76. [In Persian].
  19. Maurya RP, Prajapat MK, Singh VP, Roy M, Todi R, Bosak S, et al. Serum malondialdehyde as a biomarker of oxidative stress in patients with primary ocular carcinoma: impact on response to chemotherapy. Clin Ophthalmol 2021; 15: 871-9.
  20. Bernau K, Leet JP, Bruhn EM, Tubbs AJ, Zhu T, Sandbo N. Expression of serum response factor in the lung mesenchyme is essential for development of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2021; 321(1): L174-L188.
  21. Rafieian S, Alavi SA, Mirkheshti N, Sadeghizadeh A. The effect of thalidomide on bleomycin-induced pulmonary fibrosis in rats. J Isfahan Med Sch 2009; 97(27): 374-9. [In Persian].
  22. Yu X, Li L, Zheng L, Li W. [Differential mRNA expression in C57BL/6 mice with bleomycin-induced pulmonary fibrosis and its association with LncRNA co-expression network]. Nan Fang Yi Ke Da Xue Xue Bao 2021; 41(1): 39-46.
  23. Nagler A, Firman N, Feferman R, Cotev S, Pines M, Shoshan S. Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med 1996; 154(4 Pt 1): 1082-6.
  24. El-Medany A, Hagar HH, Moursi M, At MR, El-Rakhawy FI, El-Medany G. Attenuation of bleomycin-induced lung fibrosis in rats by mesna. Eur J Pharmacol 2005; 509(1): 61-70.
  25. Wang J, Fang C, Wang S, Fang F, Chu X, Liu N, et al. Danggui Buxue Tang ameliorates bleomycin-induced pulmonary fibrosis in rats through inhibiting transforming growth factor-beta1/Smad3/ plasminogen activator inhibitor-1 signaling pathway. J Tradit Chin Med 2020; 40(2): 236-44.
  26. Parra ER, Lin F, Martins V, Rangel MP, Capelozzi VL. Immunohistochemical and morphometric evaluation of COX 1 and COX-2 in the remodeled lung in idiopathic pulmonary fibrosis and systemic sclerosis. J Bras Pneumol 2013; 39(6): 692-700.
  27. Lappi-Blanco E, Kaarteenaho-Wiik R, Maasilta PK, Anttila S, Paakko P, Wolff HJ. COX-2 is widely expressed in metaplastic epithelium in pulmonary fibrous disorders. Am J Clin Pathol 2006; 126(5): 717-24.
  28. Handa T, Watanabe K, Tanizawa K, Oga T, Aihara K, Ikezoe K, et al. Platelet aggregability in patients with interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33(2): 143-50.
  29. Okada M, Ekimoto H, Ito J, Takahashi K. Effects of anti-platelet aggregating agents on peplomycin induced pulmonary toxicity in mice. Nihon Gan Chiryo Gakkai Shi 1989; 24(4): 793-7. [In Chinese].
  30. Zavar Reza J, Danesh Pouya F, Jalali B, Shahmoradi H. In-vitro study of homocysteine and aspirin effects on coagulation and clot permeability. J Isfahan Med Sch 2013; 31(262): 1932-40. [In Persian].
  31. Shalom A, Westreich M. Effect of high dose and low dose aspirin on survival of random pattern flaps in rats. Scand J Plast Reconstr Surg Hand Surg 2001; 35(2): 117-21.

Files

History

  • Receive Date: 30 May 2021
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics